NR1H4 and cholestasis: Ursodeoxycholic acid (UDCA), a 7-OH epimer of CDCA, previously proposed as an FXR antagonist, improved human cholestasis by decreasing Rubicon expression, providing a novel therapeutic mechanism for cholestatic patients [117,118,119].